Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is:
To assess the virologic effect of changing enfuvirtide to MK-0518(raltegravir) in human
immunodeficiency virus type 1(HIV-1) infected patients who have an undetectable level of
serum human immunodeficiency virus(HIV) (< 75 copies/ml by branch deoxyribonucleic acid
(bDNA) assay, < 50 copies/ml by Ultrasensitive Polymerase Chain Reaction(PCR) assay) on their
current HIV medication regimen.
Hypothesis:
HIV-1 infected individuals well controlled on an enfuvirtide containing regimen with HIV RNA
levels below limits of quantification can safely have the investigational integrase
inhibitor, MK-0518 substituted for enfuvirtide without loss of virologic suppression.